Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inclisiran add-on to optimized statin therapy in hypercholesterolemia
2024-511263-28-00Phase 4Completed
- Sponsor
- Novartis
- Start
- Jul 2024
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 8
01
Overview
Phase 4, randomised, double-blind trial in hypercholesterolemia, familial hypercholesterolemia (FH), atherosclerotic disease and 2 more comparing Inclisiran + optimized statin with Placebo + optimized statin (2 arms). Primary endpoint: Proportion of participants achieving individual LDL-C target at day 90. Started Jul 2024; status: completed.
02
Drugs
inclisiran
03
Conditions
hypercholesterolemiafamilial hypercholesterolemia (FH)atherosclerotic diseasediabetes mellitus type 1 (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2024-511263-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511263-28-00.